ClinicalTrials.gg
TerminatedNCT01345630MODERNUpdated Jan 14, 2016Results posted

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

A Phase 3 interventional study of Maraviroc and Emtricitabine/tenofovir in HIV-1, sponsored by ViiV Healthcare. Terminated at 177 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-14.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
813
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess whether maraviroc administered once daily is non-inferior to emtricitabine/tenofovir also administered once daily each in combination with darunavir/ritonavir in the treatment of antiretroviral-naive patients as evaluated at Week 48 of treatment.

Read the detailed description

The study was terminated on October 8, 2013 following a preliminary review of the Week 48 primary efficacy data by the study's external independent Data Monitoring Committee (DMC). The DMC assessed the data as demonstrating significant differences between the treatment arms in virologic responses and failures. The DMC recommended and the Sponsor concurred that the study be terminated because of the inferior efficacy of the Maraviroc arm as compared to the comparator arm (Emtricitabine/Tenofovir).

02

Conditions studied

  • HIV-1

Browse trials for

Keywords

  • Double-blind
  • comparative
  • trial
  • maraviroc
  • versus
  • emtricitabine/tenofovir
  • both with darunavir/ritonavir
  • antiretroviral-naive
  • Ccr5 tropic
  • Hiv 1
  • patients.
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 813 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Plasma -1 RNA equal to or greater than 1,000 copies/mL measured at the Screening Visit.
  • equal to or greater than 100 cells/mm3 at Screening.
  • Have only R5 HIV 1 at Screening as verified by a randomized tropism assay.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any other antiretroviral therapy for more than 14 days at any time.
  • Any evidence of genotypic/phenotypic resistance to darunavir, tenofovir, and emtricitabine.
  • CXCR4 using virus detected using randomized tropism determination or repeated failure to obtain an interpretable tropism result.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
813 participants (actual)

Study arms

  • Experimental
    Maraviroc

    Maraviroc 150 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for emtricitabine/tenofovir once daily.

    Drug: Maraviroc · Drug: darunavir/ritonavir 800/100 mg · Drug: placebo for maraviroc

  • Active comparator
    Emtricitabine/tenofovir

    Emtricitabine/tenofovir 200/300 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for maraviroc once daily.

    Drug: Emtricitabine/tenofovir · Drug: placebo for emtricitabine/tenofovir

Interventions

  • Maraviroc tablet 150 mg once daily for 96 weeks.

    Also known as: Selzentry, Celsentri

  • DrugEmtricitabine/tenofovir

    Drug pages: Emtricitabine · Tenofovir

    Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.

    Also known as: Truvada

  • Drugdarunavir/ritonavir 800/100 mg

    darunavir/ritonavir 800/100 mg

  • Drugplacebo for emtricitabine/tenofovir

    placebo for emtricitabine/tenofovir

    Also known as: Truvada

  • Drugplacebo for maraviroc

    placebo for maraviroc

    Also known as: Selzentry, Celsentri

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.

    The proportion of participants who achieved HIV-1 RNA \<50 copies/mL at week 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm used the plasma HIV-1 RNA in the Week 48 visit window, followed the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.

    Time frame: Week 48

Secondary outcomes

  1. Frequency of Adverse Events (AE).

    Number of participants with treatment-emergent non serious AEs

    Time frame: Week 96

  2. Number of Participants With Grade 3 or 4 AEs

    Number of participants with grade 3 or 4 AEs are presented here.

    Time frame: Week 96

  3. Number of Participants Who Discontinued Due to AEs

    Number of participants who discontinued due to AEs are reported here. Three participants (two from the MVC+DRV/r arm and one from the FTC/TDF+DRV/r arm) were not considered as discontinued due to AE because other reasons for discontinuation were prioritized for these participants.

    Time frame: Week 96

  4. Number of Treatment-related AEs

    Number of treatment-related AEs are presented here.

    Time frame: Week 96

  5. Number of Participants With Treatment-emergent Serious Adverse Events

    Total number of participants with treatment-emergent serious adverse events are reported

    Time frame: Week 96

  6. Number of Participants With Abnormal Laboratory Values

    Number of participants with laboratory abnormalities are reported

    Time frame: Week 96

  7. Severity of Abnormal Laboratory Values

    Number of participants who had clinically significant laboratory abnormalities of Grade 3 and Grade 4 according to DAIDS. Abnormality incidence of highest grade was reported for a labcode for each individual participant.

    Time frame: Week 96

  8. The Relationship Between the Proportion of Participants With Plasma HIV-1 RNA <50 Copies/mL at the Week 48 and the Screening Tropism Test (Genotype Test or ESTA).

    The relationship of the proportion of participants achieving HIV-1 RNA \<50 copies/mL at Week 48 with the screening tropism test for the MVC containing regimen was analyzed. Virologic response for a participant at Week 48 was derived using the FDA's Snapshot MSDF algorithm. Difference in proportions of patients with plasma HIV-1 RNA \<50 copies/mL at week 48 between the maraviroc and the emtricitabine/tenofovir treatment arms, with two-sided 95% confidence interval, among patients who are R5 by genotype (including some who were originally randomized to ESTA and are R5 by genotype upon retesting), were calculated via the Maximum Likelihood method. The estimate was adjusted for the screening plasma HIV RNA level (\<100,000 vs. ≥100,000) copies/mL via the Mantel Haenszel (MH) method.

    Time frame: Week 48

  9. Virologic Outcomes at Week 48 Using Protocol-Defined Treatment Failure (PDTF).

    Per the protocol participants who meet the following criteria were regarded as PDTFs requiring a confirmatory plasma HIV-1 RNA determination: • Decrease in plasma HIV-1 RNA \<1 log10 from baseline after Week 4 unless plasma HIV-1 RNA is \<50 copies/mL, or • Plasma HIV-1 RNA \>1.0 log10 above the nadir value after Week 4 where the nadir is the lowest plasma HIV-1 RNA concentration, or • Plasma HIV-1 RNA ≥50 copies/mL at any time after Week 24, or • Plasma HIV-1 RNA ≥50 copies/mL after suppression to \<50 copies/mL on two consecutive visits, or • Decrease in plasma HIV-1 RNA ≤2 log10 from baseline on or after Week 12 unless plasma HIV-1 RNA is \<400 copies/mL. Decrease in plasma HIV-1 RNA ≤2 log10 from baseline on or after Week 12 unless plasma HIV-1 RNA is \<50 copies/mL (before August 30 2012) or \<400 copies/mL (after August 30 2012).

    Time frame: Week 48

  10. Tropism Change Between Screening or Baseline and PDTF

    For participants meeting the PDTF criteria, tropism was assessed using the original randomized and alternate assays (ie, both genotype testing and ESTA). Data reported here corresponds to the timepoint at or after PDTF.

    Time frame: Week 48

  11. Number of Participants With Viral Resistance to Maraviroc (Maraviroc Treated Participants Only) in Participants Meeting PDTF Criteria.

    For participants meeting the PDTF criteria, viral resistance to maraviroc for maraviroc treated participants was assessed in patients with R5 virus at failure. The resistance level is calculated by reference to a laboratory strain of virus that is analyzed in parallel with the clinical isolate to identify 50% inhibitory concentrations (IC50). The maximal percent inhibition is the percent inhibition that is achieved in a titration of the drug at high concentrations when the addition of more drug does not result in increased inhibition. Maximal percent inhibition is obtained in the same way as the titration for IC50, but the key measure is of the plateau height of percent inhibition, where increased concentration of maraviroc does not result in additional inhibition. This is consistent with the virus developing some ability to use maraviroc-bound CCR5 for entry. A significant change in IC50 is not required for this mechanism.

    Time frame: Week 48

  12. Number of Participants With Resistance to Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI), and Protease Inhibitors (PI) in Participants Meeting PDTF Criteria

    For participants meeting the PDTF criteria, viral resistance (both genotypic and phenotypic) to NRTI, NNRTI, and PI's were assessed at Baseline and on-treatment. The assessment was performed using the overall (i.e. net) susceptibility score provided using the PhenoSense GT assay. The number of participants with successful assessments were 15/17 for the MVC+DRV/r arm and 3/3 for the FTC/TDF+DRV/r arm.

    Time frame: Week 48

  13. Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 4 (CD4, Cell/mm^3)

    The differences in the magnitude of changes in CD4+ at Baseline and at Week 48 for maraviroc versus emtricitabine/tenofovir were compared.

    Time frame: Baseline, Week 48

  14. Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD4 (%)

    The differences in the magnitude of changes in CD4+ from Baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.

    Time frame: Baseline, Week 48

  15. Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 8 (CD8, Cell/mm^3)

    The differences in the magnitude of changes in CD8+ cell counts from baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.

    Time frame: Baseline, Week 48

  16. Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD8 (%)

    The differences in the magnitude of changes in CD8+ cell counts from Baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.

    Time frame: Baseline, Week 48

  17. Absolute Change in CD4+/CD8+ Ratio From Baseline to Week 48

    The differences in the magnitude of changes in CD4+/CD8+ ratio from Baseline through Weeks 48 for maraviroc versus emtricitabine/tenofovir were compared.

    Time frame: Baseline, Week 48

  18. Changes in Peripheral Fat Distribution Using Dual Energy X-ray Absorptiometry [DEXA] Scan From Baseline and at Week 48.

    A sub-study was conducted in which the participants underwent whole-body DEXA scans to evaluate peripheral fat tissue estimates for left and right arms and legs and truncal fat mass and truncal lean mass. Truncal abdominal fat were estimated from the DEXA scan field set on the torso. The effects on estimates of fat mass and lean mass were addressed by providing LSMs of change from baseline.

    Time frame: Week 48

  19. Changes in Trunk to Limb Fat Distribution Using DEXA Scan From Baseline and at Week 48

    A sub-study was conducted in which the participants underwent whole-body DEXA scans to evaluate peripheral fat tissue estimates for left and right arms and legs and truncal fat mass and truncal lean mass. Truncal abdominal fat were estimated from the DEXA scan field set on the torso. The effects on estimates of fat mass and lean mass were addressed by providing LSMs of change from baseline.

    Time frame: Week 48

  20. Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Total Hip BMD

    Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from baseline bone mineral density of the lumbar spine (L1-L4), left total hip and femoral neck as measured by the DEXA scan.

    Time frame: Week 48

  21. Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Femoral Neck BMD

    Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from Baseline bone mineral density femoral neck as measured by the DEXA scan.

    Time frame: Week 48

  22. Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - AP Lumbar Spine (L1 - L4) BMD

    Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from baseline bone mineral density of the lumbar spine (L1-L4) as measured by the DEXA scan.

    Time frame: Week 48

  23. Change in Bone Turnover Markers From Baseline and at Week 48 - Blood Osteocalcin

    Bone turnover marker, osteocalcin, was collected in the subset of participants participating in the DEXA scan sub-study.

    Time frame: Week 48

  24. Change in Bone Turnover Markers From Baseline and at Week 48 - Type 1 Collagen Peptide (CTX-1)

    Bone turnover marker, C-telopeptide of type 1 collagen (CTx), was collected in the subset of participants participating in the DEXA scan sub-study.

    Time frame: Week 48

07

Results

Posted Jan 14, 2016
Limitations and caveats
The study was terminated following a preliminary review of the 48- week primary clinical efficacy data by the study's external independent Data Monitoring Committee's recommendation based on inferior efficacy of the investigational MVC+DRV/r arm.

Participant flow

Overall, 1423 participants were screened and 813 participants randomized in the study. A total of 797 participants were treated (396 were treated in the maraviroc + darunavir/ritonavir \[MVC+DRV/r\] group and 401 in the emtricitabine/tenofovir + darunavir/ritonavir \[FTC/TDF+DRV/r\] group). The study was conducted in 138 sites in 18 countries.

Participant flow — Overall Study
MilestoneMVC+DRV/rFTC/TDF+DRV/r
Started396401
Completed3542
Not completed361359
Withdrew: Adverse event2223
Withdrew: Lost to follow-up1716
Withdrew: Protocol violation41
Withdrew: Medication error without associated ae01
Withdrew: Study terminated by sponsor254285
Withdrew: Other reasons68
Withdrew: Withdrawn due to pregnancy12
Withdrew: No longer willing to participate912
Withdrew: Insufficient clinical response4811

Outcome measures

PrimaryPercentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.

The proportion of participants who achieved HIV-1 RNA \<50 copies/mL at week 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm used the plasma HIV-1 RNA in the Week 48 visit window, followed the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.
Percentage of participantsMVC+DRV/rFTC/TDF+DRV/r
Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.77.386.8
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · Mean difference (final values): -9.54 · 95% CI -14.83 to -4.24
SecondaryFrequency of Adverse Events (AE).

Number of participants with treatment-emergent non serious AEs

Time frame:
Week 96
Reported as:
Number · participants
Frequency of Adverse Events (AE).
participantsMVC+DRV/rFTC/TDF+DRV/r
Frequency of Adverse Events (AE).360365
SecondaryNumber of Participants With Grade 3 or 4 AEs

Number of participants with grade 3 or 4 AEs are presented here.

Time frame:
Week 96
Reported as:
Number · participants
Number of Participants With Grade 3 or 4 AEs
participantsMVC+DRV/rFTC/TDF+DRV/r
Number of Participants With Grade 3 or 4 AEs6571
SecondaryNumber of Participants Who Discontinued Due to AEs

Number of participants who discontinued due to AEs are reported here. Three participants (two from the MVC+DRV/r arm and one from the FTC/TDF+DRV/r arm) were not considered as discontinued due to AE because other reasons for discontinuation were prioritized for these participants.

Time frame:
Week 96
Reported as:
Number · participants
Number of Participants Who Discontinued Due to AEs
participantsMVC+DRV/rFTC/TDF+DRV/r
Number of Participants Who Discontinued Due to AEs2223
SecondaryNumber of Treatment-related AEs

Number of treatment-related AEs are presented here.

Time frame:
Week 96
Reported as:
Number · events
Number of Treatment-related AEs
eventsMVC+DRV/rFTC/TDF+DRV/r
Number of Treatment-related AEs316361
SecondaryNumber of Participants With Treatment-emergent Serious Adverse Events

Total number of participants with treatment-emergent serious adverse events are reported

Time frame:
Week 96
Reported as:
Number · participants
Number of Participants With Treatment-emergent Serious Adverse Events
participantsMVC+DRV/rFTC/TDF+DRV/r
Number of Participants With Treatment-emergent Serious Adverse Events4140
SecondaryNumber of Participants With Abnormal Laboratory Values

Number of participants with laboratory abnormalities are reported

Time frame:
Week 96
Reported as:
Number · participants
Number of Participants With Abnormal Laboratory Values
participantsMVC+DRV/rFTC/TDF+DRV/r
Normal Baseline210205
Abnormal Baseline111101
SecondarySeverity of Abnormal Laboratory Values

Number of participants who had clinically significant laboratory abnormalities of Grade 3 and Grade 4 according to DAIDS. Abnormality incidence of highest grade was reported for a labcode for each individual participant.

Time frame:
Week 96
Reported as:
Number · participants
Severity of Abnormal Laboratory Values
participantsMVC+DRV/rFTC/TDF+DRV/r
Alanine Aminotransferase (ALT) (n=396, 400)96
Alkaline Phosphatase (n=396, 400)10
Amylase (n=396, 400)513
Aspartate Aminotransferase (AST) (n=396, 400)117
Blood Urea Nitrogen (BUN) (n=396, 400)35
Calcium (n=396, 400)710
Creatine Kinase (n=396, 400)1822
Hemoglobin (n=396, 400)42
LDL Cholesterol (n=396, 400)5024
Lipase (n=116, 122)310
Lymphocytes (Abs) (n=396, 400)22
Phosphate (n=396, 400)512
Platelets (n=396, 400)51
Potassium (n=396, 400)32
Sodium (n=396, 400)20
Total Bilirubin (n=396, 400)31
Total Neutrophils (Abs) (n=396, 400)62
Triglycerides (n=396, 400)46
Uric Acid (n=396, 400)02
White Blood Cell Count (n=396, 400)10
Creatinine (n=396, 400)01
SecondaryThe Relationship Between the Proportion of Participants With Plasma HIV-1 RNA <50 Copies/mL at the Week 48 and the Screening Tropism Test (Genotype Test or ESTA).

The relationship of the proportion of participants achieving HIV-1 RNA \<50 copies/mL at Week 48 with the screening tropism test for the MVC containing regimen was analyzed. Virologic response for a participant at Week 48 was derived using the FDA's Snapshot MSDF algorithm. Difference in proportions of patients with plasma HIV-1 RNA \<50 copies/mL at week 48 between the maraviroc and the emtricitabine/tenofovir treatment arms, with two-sided 95% confidence interval, among patients who are R5 by genotype (including some who were originally randomized to ESTA and are R5 by genotype upon retesting), were calculated via the Maximum Likelihood method. The estimate was adjusted for the screening plasma HIV RNA level (\<100,000 vs. ≥100,000) copies/mL via the Mantel Haenszel (MH) method.

Time frame:
Week 48
Reported as:
Number · proportion of participants
The Relationship Between the Proportion of Participants With Plasma HIV-1 RNA <50 Copies/mL at the Week 48 and the Screening Tropism Test (Genotype Test or ESTA).
proportion of participantsMVC+DRV/rFTC/TDF+DRV/r
The Relationship Between the Proportion of Participants With Plasma HIV-1 RNA <50 Copies/mL at the Week 48 and the Screening Tropism Test (Genotype Test or ESTA).0.8047 ± 0.02380.8797 ± 0.0187
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · Treatment difference: -0.0750 · 95% CI -0.1343 to -0.0157
SecondaryVirologic Outcomes at Week 48 Using Protocol-Defined Treatment Failure (PDTF).

Per the protocol participants who meet the following criteria were regarded as PDTFs requiring a confirmatory plasma HIV-1 RNA determination: • Decrease in plasma HIV-1 RNA \<1 log10 from baseline after Week 4 unless plasma HIV-1 RNA is \<50 copies/mL, or • Plasma HIV-1 RNA \>1.0 log10 above the nadir value after Week 4 where the nadir is the lowest plasma HIV-1 RNA concentration, or • Plasma HIV-1 RNA ≥50 copies/mL at any time after Week 24, or • Plasma HIV-1 RNA ≥50 copies/mL after suppression to \<50 copies/mL on two consecutive visits, or • Decrease in plasma HIV-1 RNA ≤2 log10 from baseline on or after Week 12 unless plasma HIV-1 RNA is \<400 copies/mL. Decrease in plasma HIV-1 RNA ≤2 log10 from baseline on or after Week 12 unless plasma HIV-1 RNA is \<50 copies/mL (before August 30 2012) or \<400 copies/mL (after August 30 2012).

Time frame:
Week 48
Reported as:
Number · Number of participants
Virologic Outcomes at Week 48 Using Protocol-Defined Treatment Failure (PDTF).
Number of participantsMVC+DRV/rFTC/TDF+DRV/r
Confirmed PDTF4013
Evaluable PDTF173
SecondaryTropism Change Between Screening or Baseline and PDTF

For participants meeting the PDTF criteria, tropism was assessed using the original randomized and alternate assays (ie, both genotype testing and ESTA). Data reported here corresponds to the timepoint at or after PDTF.

Time frame:
Week 48
Reported as:
Number · participants
Tropism Change Between Screening or Baseline and PDTF
participantsMVC+DRV/r - BaselineMVC+DRV/r - FailureFTC/TDF+DRV/r - BaselineFTC/TDF+DRV/r - Failure
R5 (Randomized Assay)141321
NON R5 (Randomized Assay)1100
NR (Randomized Assay)2312
R5 (Alternate Assay)101032
NON R5 (Alternate Assay)2301
NR (Alternate Assay)5400
SecondaryNumber of Participants With Viral Resistance to Maraviroc (Maraviroc Treated Participants Only) in Participants Meeting PDTF Criteria.

For participants meeting the PDTF criteria, viral resistance to maraviroc for maraviroc treated participants was assessed in patients with R5 virus at failure. The resistance level is calculated by reference to a laboratory strain of virus that is analyzed in parallel with the clinical isolate to identify 50% inhibitory concentrations (IC50). The maximal percent inhibition is the percent inhibition that is achieved in a titration of the drug at high concentrations when the addition of more drug does not result in increased inhibition. Maximal percent inhibition is obtained in the same way as the titration for IC50, but the key measure is of the plateau height of percent inhibition, where increased concentration of maraviroc does not result in additional inhibition. This is consistent with the virus developing some ability to use maraviroc-bound CCR5 for entry. A significant change in IC50 is not required for this mechanism.

Time frame:
Week 48
Reported as:
Number · participants
Number of Participants With Viral Resistance to Maraviroc (Maraviroc Treated Participants Only) in Participants Meeting PDTF Criteria.
participantsMVC+DRV/rFTC/TDF+DRV/r
Not eligible for analysis (failed tropism test)41
Not eligible for analysis (non-R5 tropism)11
Eligible for analysis (R5 virus using ESTA)121
Results reported121
Maximal percent inhibition <95%00
IC50 FC ≥3.000
SecondaryNumber of Participants With Resistance to Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI), and Protease Inhibitors (PI) in Participants Meeting PDTF Criteria

For participants meeting the PDTF criteria, viral resistance (both genotypic and phenotypic) to NRTI, NNRTI, and PI's were assessed at Baseline and on-treatment. The assessment was performed using the overall (i.e. net) susceptibility score provided using the PhenoSense GT assay. The number of participants with successful assessments were 15/17 for the MVC+DRV/r arm and 3/3 for the FTC/TDF+DRV/r arm.

Time frame:
Week 48
Reported as:
Number · participants
Number of Participants With Resistance to Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI), and Protease Inhibitors (PI) in Participants Meeting PDTF Criteria
participantsMVC+DRV/rFTC/TDF+DRV/r
NRTI - All (Baseline, n=15, 3)00
NNRTI Delavirdine (Baseline, n=15, 3)10
NNRTI Nevirapine (Baseline, n=15, 3)10
NNRTI Efavirenz (Baseline, n=15, 3)10
PRI - All (Baseline, n=15, 3)00
NRTI - All (PDTF, n=15, 3)00
NNRTI Delavirdine (PDTF, n=15, 3)10
NNRTI Nevirapine (PDTF, n=15, 3)10
NNRTI Efavirenz (PDTF, n=15, 3)10
PRI - All (PDTF, n=15, 3)00
SecondaryAbsolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 4 (CD4, Cell/mm^3)

The differences in the magnitude of changes in CD4+ at Baseline and at Week 48 for maraviroc versus emtricitabine/tenofovir were compared.

Time frame:
Baseline, Week 48
Reported as:
Mean · cell/mm^3
Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 4 (CD4, Cell/mm^3)
cell/mm^3MVC+DRV/rFTC/TDF+DRV/r
Baseline (n=396, 401)382.0 ± 173.4379.5 ± 170.9
Week 48 (n=394, 396)576.9 ± 226.0574.6 ± 232.1
Change from Baseline at Week 48 (n=394, 396)194.9 ± 175.5194.2 ± 175.8
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · ANCOVA · p = 0.9750 · Mean difference (final values): -0.4 · 95% CI -24.4 to 23.6
SecondaryPercent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD4 (%)

The differences in the magnitude of changes in CD4+ from Baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.

Time frame:
Baseline, Week 48
Reported as:
Mean · Percentage of lymphocytes
Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD4 (%)
Percentage of lymphocytesMVC+DRV/rFTC/TDF+DRV/r
Baseline (n=396, 401)24.2 ± 7.924.5 ± 8.2
Week 48 (n=394, 396)31.3 ± 8.333.7 ± 8.6
Change from Baseline at Week 48 (n=394, 396)7.0 ± 5.79.2 ± 6.0
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · ANCOVA · p = <0.0001 · Mean difference (final values): -2.3 · 95% CI -3.1 to -1.5
SecondaryAbsolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 8 (CD8, Cell/mm^3)

The differences in the magnitude of changes in CD8+ cell counts from baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.

Time frame:
Baseline, Week 48
Reported as:
Mean · cell/mm^3
Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 8 (CD8, Cell/mm^3)
cell/mm^3MVC+DRV/rFTC/TDF+DRV/r
Baseline (n=396, 401)954.4 ± 502.1914.5 ± 473.0
Week 48 (n=394, 396)900.0 ± 508.3751.1 ± 386.7
Change from Baseline at Week 48 (n=394, 396)-49.9 ± 410.7-157.9 ± 444.0
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · ANCOVA · p = <0.0001 · Mean difference (final values): 127.7 · 95% CI 76.5 to 178.8
SecondaryPercent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD8 (%)

The differences in the magnitude of changes in CD8+ cell counts from Baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.

Time frame:
Baseline, Week 48
Reported as:
Mean · Percentage of lymphocytes
Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD8 (%)
Percentage of lymphocytesMVC+DRV/rFTC/TDF+DRV/r
Baseline (n=396, 401)57.0 ± 10.755.8 ± 10.5
Week 48 (n=394, 396)46.0 ± 10.443.0 ± 10.2
Change from Baseline at Week 48 (n=394, 396)-10.9 ± 7.2-12.6 ± 8.1
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · ANCOVA · p = <0.0001 · Mean difference (final values): 2.1 · 95% CI 1.1 to 3.1
SecondaryAbsolute Change in CD4+/CD8+ Ratio From Baseline to Week 48

The differences in the magnitude of changes in CD4+/CD8+ ratio from Baseline through Weeks 48 for maraviroc versus emtricitabine/tenofovir were compared.

Time frame:
Baseline, Week 48
Reported as:
Mean · Ratio
Absolute Change in CD4+/CD8+ Ratio From Baseline to Week 48
RatioMVC+DRV/rFTC/TDF+DRV/r
Baseline (n=396, 401)0.47 ± 0.240.48 ± 0.25
Week 48 (n=394, 396)0.75 ± 0.340.87 ± 0.45
Change from Baseline at Week 48 (n=394, 396)0.28 ± 0.220.39 ± 0.34
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · ANCOVA · p = <0.0001 · Mean difference (final values): -0.11 · 95% CI -0.15 to -0.07
SecondaryChanges in Peripheral Fat Distribution Using Dual Energy X-ray Absorptiometry [DEXA] Scan From Baseline and at Week 48.

A sub-study was conducted in which the participants underwent whole-body DEXA scans to evaluate peripheral fat tissue estimates for left and right arms and legs and truncal fat mass and truncal lean mass. Truncal abdominal fat were estimated from the DEXA scan field set on the torso. The effects on estimates of fat mass and lean mass were addressed by providing LSMs of change from baseline.

Time frame:
Week 48
Reported as:
Least squares mean · gram
Changes in Peripheral Fat Distribution Using Dual Energy X-ray Absorptiometry [DEXA] Scan From Baseline and at Week 48.
gramMVC+DRV/rFTC/TDF+DRV/r
Changes in Peripheral Fat Distribution Using Dual Energy X-ray Absorptiometry [DEXA] Scan From Baseline and at Week 48.-181.6 ± 569.8-257.5 ± 556.9
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · ANCOVA · p = 0.8379 · Mean difference (final values): 75.861 · 95% CI -658.181 to 809.903
SecondaryChanges in Trunk to Limb Fat Distribution Using DEXA Scan From Baseline and at Week 48

A sub-study was conducted in which the participants underwent whole-body DEXA scans to evaluate peripheral fat tissue estimates for left and right arms and legs and truncal fat mass and truncal lean mass. Truncal abdominal fat were estimated from the DEXA scan field set on the torso. The effects on estimates of fat mass and lean mass were addressed by providing LSMs of change from baseline.

Time frame:
Week 48
Reported as:
Least squares mean · ratio
Changes in Trunk to Limb Fat Distribution Using DEXA Scan From Baseline and at Week 48
ratioMVC+DRV/rFTC/TDF+DRV/r
Changes in Trunk to Limb Fat Distribution Using DEXA Scan From Baseline and at Week 480.017 ± 0.048-0.014 ± 0.048
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · ANCOVA · p = 0.3376 · Mean difference (final values): 0.031 · 95% CI -0.033 to 0.094
SecondaryChanges in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Total Hip BMD

Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from baseline bone mineral density of the lumbar spine (L1-L4), left total hip and femoral neck as measured by the DEXA scan.

Time frame:
Week 48
Reported as:
Least squares mean · g/cm^2
Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Total Hip BMD
g/cm^2MVC+DRV/rFTC/TDF+DRV/r
Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Total Hip BMD-0.014 ± 0.005-0.028 ± 0.005
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · ANCOVA · p = 0.0043 · Mean difference (final values): 0.014 · 95% CI 0.004 to 0.023
SecondaryChanges in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Femoral Neck BMD

Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from Baseline bone mineral density femoral neck as measured by the DEXA scan.

Time frame:
Week 48
Reported as:
Least squares mean · g/cm^2
Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Femoral Neck BMD
g/cm^2MVC+DRV/rFTC/TDF+DRV/r
Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Femoral Neck BMD-0.021 ± 0.007-0.029 ± 0.007
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · ANCOVA · p = 0.2273 · Mean difference (final values): 0.008 · 95% CI -0.005 to 0.022
SecondaryChanges in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - AP Lumbar Spine (L1 - L4) BMD

Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from baseline bone mineral density of the lumbar spine (L1-L4) as measured by the DEXA scan.

Time frame:
Week 48
Reported as:
Least squares mean · g/cm^2
Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - AP Lumbar Spine (L1 - L4) BMD
g/cm^2MVC+DRV/rFTC/TDF+DRV/r
Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - AP Lumbar Spine (L1 - L4) BMD-0.020 ± 0.006-0.025 ± 0.006
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · ANCOVA · p = 0.4188 · Mean difference (final values): 0.005 · 95% CI -0.007 to 0.018
SecondaryChange in Bone Turnover Markers From Baseline and at Week 48 - Blood Osteocalcin

Bone turnover marker, osteocalcin, was collected in the subset of participants participating in the DEXA scan sub-study.

Time frame:
Week 48
Reported as:
Mean · ng/mL
Change in Bone Turnover Markers From Baseline and at Week 48 - Blood Osteocalcin
ng/mLMVC+DRV/rFTC/TDF+DRV/r
Change in Bone Turnover Markers From Baseline and at Week 48 - Blood Osteocalcin5.61 ± 8.026.77 ± 8.31
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · ANCOVA · p = 0.1722 · Mean difference (final values): -2.12 · 95% CI -5.17 to 0.94
SecondaryChange in Bone Turnover Markers From Baseline and at Week 48 - Type 1 Collagen Peptide (CTX-1)

Bone turnover marker, C-telopeptide of type 1 collagen (CTx), was collected in the subset of participants participating in the DEXA scan sub-study.

Time frame:
Week 48
Reported as:
Mean · pg/mL
Change in Bone Turnover Markers From Baseline and at Week 48 - Type 1 Collagen Peptide (CTX-1)
pg/mLMVC+DRV/rFTC/TDF+DRV/r
Change in Bone Turnover Markers From Baseline and at Week 48 - Type 1 Collagen Peptide (CTX-1)121.13 ± 243.03223.52 ± 293.03
Statistical analysis
  • MVC+DRV/r vs FTC/TDF+DRV/r · ANCOVA · p = 0.0071 · Mean difference (final values): -126.78 · 95% CI -218.34 to -35.23

Adverse events

Collected over From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MVC+DRV/r—41/396 (10.4%)257/396 (64.9%)
FTC/TDF+DRV/r—40/401 (10%)285/401 (71.1%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventMVC+DRV/rFTC/TDF+DRV/r
ColitisGastrointestinal disorders2/3960/401
Chest painGeneral disorders2/3961/401
Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3960/401
DepressionPsychiatric disorders2/3961/401
Acute hepatitis CInfections and infestations0/3962/401
Toxicity to various agentsInjury, poisoning and procedural complications1/3962/401
RhabdomyolysisMusculoskeletal and connective tissue disorders0/3962/401
Suicidal ideationPsychiatric disorders1/3962/401
Suicide attemptPsychiatric disorders1/3962/401
Drug rehabilitationSurgical and medical procedures0/3962/401
Most frequent other events
Showing 10 of 18
Most frequent other events
EventMVC+DRV/rFTC/TDF+DRV/r
DiarrhoeaGastrointestinal disorders88/396135/401
NasopharyngitisInfections and infestations48/39655/401
HeadacheNervous system disorders27/39647/401
FatigueGeneral disorders27/39646/401
NauseaGastrointestinal disorders34/39645/401
Upper respiratory tract infectionInfections and infestations40/39645/401
RashSkin and subcutaneous tissue disorders37/39630/401
CoughRespiratory, thoracic and mediastinal disorders27/39630/401
DepressionPsychiatric disorders26/39629/401
BronchitisInfections and infestations25/39624/401

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MVC+DRV/rFTC/TDF+DRV/rTotal
Mean37.9 ± 10.936.2 ± 10.937.1 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)MVC+DRV/rFTC/TDF+DRV/rTotal
Female363470
Male360367727
08

Study locations

177 sites
  • University of Alabama at Birmingham - 1917 Research Clinic
    Birmingham, Alabama 35294, United States
  • Health Services Center
    Hobson City, Alabama 36201, United States
  • Kaiser Permanente
    Hayward, California 94545, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Dr. Anthony Mills, MD, Inc.
    Los Angeles, California 90069, United States
  • Orange Coast Medical Group
    Newport Beach, California 92663, United States
  • Desert Oasis Healthcare Medical Group
    Palm Springs, California 92262, United States
  • University of California Davis Research
    Sacramento, California 95814, United States
  • TICON I Research Clinic (DEXA Scan only)
    Sacramento, California 95817, United States
  • Kaiser Hospital Sacramento
    Sacramento, California 95825, United States
  • Synarc Inc.
    San Francisco, California 94105, United States
  • Investigational Drugs Pharmacy
    San Francisco, California 94118, United States
  • Kaiser Permanente - Clinical Trials Unit
    San Francisco, California 94118, United States
  • Kaiser Permanente Santa Clara
    Santa Clara, California 95051, United States
  • Kaiser Permanente
    Union City, California 94587, United States
  • University of Colorado Denver - University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Kaiser Permanente of Colorado
    Denver, Colorado 80205, United States
  • Yale - New Haven Hospital Nathan Smith Clinic
    New Haven, Connecticut 06504, United States
  • Yale University
    New Haven, Connecticut 06510, United States
  • Circle CARE Center
    Norwalk, Connecticut 06851, United States
  • Capital Medical Associates, PC
    Washington, District of Columbia 20036, United States
  • George Washington University Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Broward Health - Comprehensive Care Center
    Fort Lauderdale, Florida 33311, United States
  • Broward General Medical Center
    Fort Lauderdale, Florida 33316, United States
  • Wohlfeiler, Piperato and Associates, LLC
    Miami Beach, Florida 33139, United States
  • The Kinder Medical Group
    Miami, Florida 33133, United States
  • UMHC/Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • University of Miami AIDS Clinical Research Unit
    Miami, Florida 33136, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Community AIDS Resource Inc dba Care Resource
    Miami, Florida 33137, United States
  • Miami Research Associates
    Miami, Florida 33143, United States
  • Infectious Diseases Associates of Northwest Florida, PA
    Pensacola, Florida 32504, United States
  • St. Joseph's Hospital Diagnostic Center
    Tampa, Florida 33067, United States
  • University of South Florida Health-HIV Clinical Research Unit
    Tampa, Florida 33602, United States
  • Infectious Disease Research Institute, Inc.
    Tampa, Florida 33614, United States
  • Osteoporosis Care Center
    Tampa, Florida 33614, United States
  • Quest Diagnostic Laboratory
    Tampa, Florida 33614, United States
  • Rowan Tree Medical, PA
    Wilton Manors, Florida 33305, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30312, United States
  • DeKalb Medical Diagnostic Breast Center
    Decatur, Georgia 30033, United States
  • Infectious Disease Specialists of Atlanta
    Decatur, Georgia 30033, United States
  • Northwestern University/NMH
    Chicago, Illinois 60611, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Howard Brown Health Center
    Chicago, Illinois 60613, United States
  • University of Iowa, University of Hospitals and Clinics - Division of Infectious Disease
    Iowa City, Iowa 52242, United States
  • Tulane University School of Medicine
    New Orleans, Louisiana 70112, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Baystate Infectious Diseases Clinical Research
    Springfield, Massachusetts 01199, United States
  • Be Well Medical Center, PC
    Berkley, Michigan 48072, United States
  • University Physicians Group
    Detroit, Michigan 48201, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Michigan State University College of Osteopathic Medicine - Department of Internal Medicine
    East Lansing, Michigan 48824, United States
  • Biomedical and Health Institutional Review Board
    East Lansing, Michigan 48825, United States
  • Ingham County Health Department
    Lansing, Michigan 48911, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • Kansas City Free Health Clinic
    Kansas City, Missouri 64111, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68106, United States
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07753, United States
  • Brandywine Common
    Neptune, New Jersey 07754, United States
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07754, United States
  • Saint Michael's Medical Center
    Newark, New Jersey 07102, United States
  • Erie County Medical Center
    Buffalo, New York 14215, United States
  • Beth Israel Medical Center - AIDS Clinical Trials Unit
    New York, New York 10003, United States
  • AIDS Community Research Initiative of America (ACRIA)
    New York, New York 10018, United States
  • Research Across America
    New York, New York 10022, United States
  • Dr. Howard A. Grossman, M.D.
    New York, New York 10107, United States
  • AIDS Care
    Rochester, New York 14607, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • I.D. Consultants, P.A.
    Charlotte, North Carolina 28209, United States
  • (DEXA Scan Facility) East Carolina University Brody Outpatient Center
    Greenville, North Carolina 27834, United States
  • East Carolina University Division of Infectious Diseases
    Greenville, North Carolina 27834, United States
  • University of Cincinnati - Department of Internal Medicine
    Cincinnati, Ohio 45267, United States
  • The University of Toledo Medical Center
    Toledo, Ohio 43614, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • Dallas Diabetes and Endocrine Center
    Dallas, Texas 75230, United States
  • Parkland Memorial Hospital
    Dallas, Texas 75235, United States
  • University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75235, United States
  • North Texas Infectious Diseases Consultants, PA
    Dallas, Texas 75246, United States
  • Therapeutic Concepts, PA
    Houston, Texas 77004, United States
  • Research Access Network
    Houston, Texas 77098, United States
  • The Office of Dr. Gordon E. Crofoot, M.D., PA
    Houston, Texas 77098, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • East Sydney Doctors
    Darlinghurst, New South Wales 2010, Australia
  • Holdsworth House General Practice
    Darlinghurst, New South Wales 2010, Australia
  • St Vincent's Hospital
    Darlinghurst, New South Wales 2010, Australia
  • Taylor Square Private Clinic
    Surry Hills, New South Wales 2010, Australia
  • Brisbane Sexual Health and HIV Service
    Brisbane, Queensland 4000, Australia
  • Melbourne Sexual Health Centre
    Carlton, Victoria 3053, Australia
  • Clinical Research Unit, Infectious Diseases
    Melbourne, Victoria 3004, Australia
  • AKH Wien Universitaetsklinik fuer Dermatologie
    Wien, 1090, Austria
  • Instituut voor Tropische Geneeskunde
    Antwerpen, B-2000, Belgium
  • C.H.U. St-Pierre
    Brussels, 1000, Belgium
  • Cliniques Universitaires St-Luc
    Brussels, 1200, Belgium
  • Hôpital Universitaire Erasme
    Bruxelles, 1070, Belgium
  • Universitair Ziekenhuis Gent
    Gent, B-9000, Belgium
  • C.H.U. Sart-Tilman
    Liege, 4000, Belgium
  • Vancouver ID Research and Care Centre Society
    Vancouver, British Columbia V6Z 2C7, Canada
  • The Ottawa Hospital-Riverside Campus
    Ottawa, Ontario K1H 7W9, Canada

Showing the first 100 of 177 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Aug 2013 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2011
First posted
May 2, 2011
Start
Sep 2011
Primary completionActual
Aug 2013
CompletionActual
Jan 2014
Results first posted
Jan 14, 2016
Last update
Jan 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01345630
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
Responsible party
Sponsor
First posted
May 2, 2011
Start date
Sep 2011
Primary completion
Aug 2013
Completion
Jan 2014
Results posted
Jan 14, 2016
Last update
Jan 14, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion